Earnings Preview: Johnson & Johnson

Johnson & Johnson (JNJ) is expected to report Q3 earnings before market open Tuesday Oct. 14, with a conference call scheduled for 8:30 am ET.

Guidance

Analysts are looking for a profit of $1.12 on revenue of $15.70B. The consensus is $1.04 to $1.16 for EPS, and revenue of $15.50B to $16.04B, according to First Call. In its Q2 earnings release, Johnson & Johnson reported EPS of $1.17 compared to consensus of $1.12 and revenue of $16.5B compared to consensus of $16B.

Analyst Views

Positive catalysts for this earnings period include sales from consumer products division and sales in medical devices. Risks to earnings for the company include generic competition especially for Risperdal. Johnson & Johnson was added to Morgan Stanley's model portfolio on September 16. On September 5, the firm rated the shares an overweight with a price target of $82.